Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y.

Exp Ther Med. 2012 Aug;4(2):188-196. Epub 2012 May 10.

2.

Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.

Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y.

Asia Pac J Clin Oncol. 2012 Jun;8(2):156-63. doi: 10.1111/j.1743-7563.2012.01542.x.

PMID:
22524574
3.

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Lee S, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH.

J Hepatocell Carcinoma. 2015 Apr 28;2:39-47. doi: 10.2147/JHC.S79353. eCollection 2015.

4.

[Clinical efficacy and prognostic factors for cryoablation patients with advanced hepatocellular carcinoma].

Chang XJ, Lu YY, Bai WL, Chen Y, An LJ, Zhou L, Wang H, Wu Y, Liu Z, Lou M, Zeng Z, Su SH, Yang YP.

Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):759-63. doi: 10.3760/cma.j.issn.1007-3418.2011.10.010. Chinese.

PMID:
22409849
5.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.

Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C, DE Vita F.

Oncol Lett. 2015 Apr;9(4):1628-1632. Epub 2015 Feb 12.

6.

Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.

J Vasc Interv Radiol. 2015 Mar;26(3):320-9.e6. doi: 10.1016/j.jvir.2014.10.019. Epub 2015 Jan 19.

PMID:
25612807
7.

Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.

Chen D, Zhao P, Li SQ, Xiao WK, Yin XY, Peng BG, Liang LJ.

Eur J Surg Oncol. 2013 Sep;39(9):974-80. doi: 10.1016/j.ejso.2013.06.018. Epub 2013 Jul 8.

PMID:
23845703
8.

Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma.

Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF.

J Gastrointest Surg. 2016 Dec;20(12):2002-2009. Epub 2016 Oct 6.

PMID:
27714643
9.

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma.

Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A.

World J Hepatol. 2013 Jul 27;5(7):364-71. doi: 10.4254/wjh.v5.i7.364.

10.

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.

Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.

Radiology. 2013 Nov;269(2):603-11. doi: 10.1148/radiol.13130150. Epub 2013 Jul 17.

PMID:
23864102
11.

Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J.

Exp Ther Med. 2012 Feb;3(2):171-180. Epub 2011 Dec 1.

12.

A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.

Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q.

Liver Int. 2015 Sep;35(9):2147-54. doi: 10.1111/liv.12805. Epub 2015 Mar 7.

PMID:
25676812
13.
14.

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.

Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M.

J Egypt Natl Canc Inst. 2014 Mar;26(1):9-13. doi: 10.1016/j.jnci.2013.08.003. Epub 2013 Sep 16.

15.

[Subcellular proteomic analysis of Tetrazanbigen on human hepatocellular carcinoma cell line QGY-7701].

Yuan YH, Yang XL, Li W, Zheng XH, Gu R, Yu Y.

Zhonghua Gan Zang Bing Za Zhi. 2011 Dec;19(12):908-11. doi: 10.3760/cma.j.issn.1007-3418.2011.12.007. Chinese.

PMID:
22525503
16.

Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.

Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C.

J BUON. 2017 Jan-Feb;22(1):150-156.

PMID:
28365948
17.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.

Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim DY, Ahn SH, Tak WY, Kweon YO, Lee JI, Lee KS, Kim HJ, Han KH.

J Gastroenterol Hepatol. 2014;29(7):1463-9. doi: 10.1111/jgh.12542.

PMID:
25273508
18.

Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.

Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ.

J Gastrointest Oncol. 2014 Aug;5(4):259-64. doi: 10.3978/j.issn.2078-6891.2014.036.

19.

Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.

Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH.

Hepatol Int. 2017 May;11(3):292-299. doi: 10.1007/s12072-017-9792-3. Epub 2017 Mar 21.

PMID:
28324324
20.

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH.

Ann Oncol. 2013 Jul;24(7):1786-92. doi: 10.1093/annonc/mdt072. Epub 2013 Mar 18.

PMID:
23508822

Supplemental Content

Support Center